| Similar Articles |
|---|
 |
The Motley Fool
August 30, 2010
Brian Orelli |
Shocker: Sanofi's Interested in Genzyme But there are a lot of reason for Genzyme's management to shun the bid. Will it come to fruition?   |
The Motley Fool
October 4, 2010
Ryan McBride |
Sanofi-Aventis Launches Hostile Takeover Bid for Genzyme The French drug giant makes a tender offer of $69 a share. |
The Motley Fool
August 30, 2010
Ryan McBride |
Genzyme Shoots Down Sanofi-Aventis's Buyout Offer Genzyme would be a prize for several major drug companies in need of new revenue streams. |
The Motley Fool
October 28, 2010
Brian Orelli |
This Takeover's Going Nowhere Fast The Sanofi-Genzyme Drama, Take 37. |
The Motley Fool
October 21, 2010
Brian Orelli |
Genzyme: Nice Quarter, Still Too Expensive After its train wreck of manufacturing problems, Genzyme seems like it's getting the cars back on track. |
The Motley Fool
August 3, 2010
Brian Orelli |
Drama Continues: What's Genzyme Worth to Sanofi? Just get on with it, Sanofi and Genzyme. How much is Genzyme worth? Whatever its board of directors is willing to let it go for. |
Chemistry World
October 5, 2010
Andrew Turley |
Sanofi hostile move for Genzyme Sanofi-Aventis has taken its $69-per-share ( 44-per-share) bid to the Genzyme shareholders, signalling its intent to acquire the US biotech with or without the support of its board. |
The Motley Fool
December 13, 2010
Brian Orelli |
Yep, We Still Want to Lowball You sanofi-aventis still wants investors shares in Genzyme, but it's not willing to step up the price. |
The Motley Fool
September 13, 2010
Brian Orelli |
When All Else Fails, Sell! Genzyme has no other choice. |
The Motley Fool
October 31, 2007
Brian Lawler |
Sanofi: Stable, for Now The drugmaker's healthy Q3 results shine amid slumping competitors. Investors, take note. |
The Motley Fool
May 7, 2007
Brian Lawler |
Sanofi Rolls the Lawsuit Dice Investors, don't be fooled by rosy results; litigation risk still looms for the French drugmaker. |
The Motley Fool
February 20, 2007
Brian Lawler |
Sanofi Sweats the Generic Drugmaker Sanofi-Aventis releases fourth-quarter earnings numbers and guidance for the year ahead. |
The Motley Fool
February 14, 2008
Brian Lawler |
Sanofi Stagnates French drugmaker Sanofi-Aventis posts fourth-quarter earnings in which its top drugs get some protection, but free cash flow drops. |
The Motley Fool
May 13, 2008
Brian Lawler |
Sanofi Can't Shake the Generics A new threat to the pharmaceutical's top drug may have arrived. |
The Motley Fool
January 29, 2007
Brian Lawler |
The Paris Hilton of Drug Stocks Yet another rumor about a potential merger for Bristol-Myers. Who is the winner in a Bristol-Myers and Sanofi-Aventis merger? It obviously depends on the price Sanofi is willing to pay. Investors, take note. |
The Motley Fool
July 26, 2010
Brian Orelli |
Beleaguered Biotech for Sale by Owner. Maybe. Will Genzyme's management sell before the turnaround is complete? |
The Motley Fool
February 17, 2011
Brian Orelli |
What Sanofi-Genzyme Means for the Rest of Biotech This is no time to celebrate. |
The Motley Fool
June 19, 2007
Brian Lawler |
Victory for Sanofi and Bristol-Myers The pharmaceutical gains a crucial legal victory for its top compound. Investors, take note. |
The Motley Fool
November 24, 2010
Brian Orelli |
Yay! We Don't Have to Pay an 18.5% Penalty Genzyme moves one step closer to a comeback. The company announced today that it had met its deadline for moving the fill-and-finish activities for drugs sold in the U.S. out of its beleaguered Allston, Mass., plant. |
The Motley Fool
April 10, 2007
Brian Lawler |
Barr Issues a Challenge Barr challenges the patents on one of Sanofi's top drugs. |
BusinessWeek
February 9, 2004
Kerry Cappell |
This Bid Looks Like Bad Medicine Sanofi's lowball offer for giant drugmaker Aventis is unwise for both companies |
The Motley Fool
October 27, 2010
Selena Maranjian |
When Hostile Takeovers Get Ugly Conflict between companies and potential buyers can spill over to hurt shareholders. |
The Motley Fool
July 28, 2010
Brian Orelli |
Fighting Hard to Keep a Blockbuster Sanofi is suing the FDA to take back approval of a competing generic drug. Did you expect something different? |
The Motley Fool
November 1, 2006
Brian Lawler |
Le Generic Excuse for Sanofi Even with its massive pipeline, there may be problems ahead for Sanofi. Its two top drugs are exposed to generic threats as Sanofi fights in court to keep generic competitiors out of those markets. Investors, take note. |
The Motley Fool
February 11, 2010
Brian Orelli |
A Turnaround Year, But Not in a Good Way 2009 was a solid year for sanofi-aventis thanks to a boost from sales of swine flu vaccine and some help from the exchange rate. But 2010? Not so solid. |
The Motley Fool
September 11, 2008
Brian Lawler |
Will a Change Cure Sanofi? The drugmaker charts a different course for its future. |
The Motley Fool
October 26, 2011
Brian Orelli |
Momenta Stopped. Again. Oh, no - an authorized generic gets launched. |
The Motley Fool
September 1, 2006
Brian Lawler |
Bristol-Myers and Sanofi Get Apotex to Stop A temporary injunction against generic drug manufacturer Apotex over patents involving Plavix means big news for all the companies involved. |
The Motley Fool
December 30, 2010
Brian Orelli |
2011 Drugmaker M&A Targets What Big Pharma M&A deals will 2011 hold? Most likely, more small deals, and perhaps Sanofi will finally offer a reasonable price for Genzyme. Let's take a look at some of the companies that might be walking down the aisle next year. |
The Motley Fool
November 18, 2010
Brian Orelli |
Genzyme: Slimmed Down, Gussied Up But will anyone buy it? |
BusinessWeek
March 29, 2004
Kerry Capell |
A Drug Behemoth In The Making? Novartis plus Aventis would create the world's No. 2 drugmaker, unless politics get in the way |
The Motley Fool
March 3, 2011
Ryan McBride |
With Sanofi Buyout of Genzyme, Rare Disease Execs Upbeat About Interest in Their Niche The field might benefit from the increased interest in it among pharmaceutical players. |
The Motley Fool
September 11, 2007
Brian Lawler |
Where Momenta Stands Momenta Pharmaceuticals updates investors as to the status of drugs in its pipeline. Until the FDA makes up its mind on its lead drug, an anticoagulant, it's anyone's guess as to what the value of the pipeline is. Investors should take note. |
The Motley Fool
July 26, 2010
Ryan McBride |
How Much Would You Pay for Genzyme? Speculation has erupted over the potential outcome of reported M&A talks between the Cambridge, MA-based biotech powerhouse Genzyme and the French drug giant Sanofi-Aventis |
The Motley Fool
September 24, 2008
Brian Lawler |
Sanofi Gets the Golden Ring Sanofi-Aventis raises its bid and acquires Czech generic drugmaker Zentiva. |
The Motley Fool
September 17, 2009
Brian Orelli |
Sleepless in Sanofi It's nothing but sleepless nights for sanofi-aventis, and there's no drug to cure it. |
The Motley Fool
October 30, 2009
Brian Orelli |
Shrugging Off the Side Effects Sanofi-aventis is looking good, but still faces the patent protection loss of Lovenox. |
The Motley Fool
July 29, 2009
Brian Orelli |
The Swine Flu Can't Save Sanofi No shocker there. |
The Motley Fool
December 11, 2006
Brian Lawler |
Weighing In on Sanofi's Acomplia With the future of Sanofi's two top drugs in the hands of the courts, plus any Acomplia approval subject to the whims of the FDA, investors should wait on the sidelines until these judicial and regulatory decisions have been made. |
The Motley Fool
February 23, 2010
Brian Orelli |
Icahn Puts His Proxy Fight Where His Money Is How patient will Carl Icahn be with Genzyme's turnaround plan? That's the $270 million question -- the value of Icahn's shares, based on his holdings at the end of the year. |
The Motley Fool
October 15, 2007
Brian Lawler |
Save Your Cash, Pfizer A multibillion-dollar stake in Sanofi wouldn't fix Pfizer's problems. Investors, take note. |
Chemistry World
January 3, 2014
Ben Valsler |
Sanofi suffers multiple sclerosis setback French pharmaceutical Sanofi has run into trouble after the US Food and Drug Administration rejected its multiple sclerosis drug Lemtrada (alemtuzumab). |
The Motley Fool
November 20, 2008
Brian Orelli |
Sanofi Breathing Easier Drugmaker Sanofi-Aventis settles a few patent disputes with generic-drugmaker nemeses. |
The Motley Fool
November 14, 2007
Brian Lawler |
Genzyme Zigs, Shares Zag Genzyme gets downbeat news that will delay the launch of its lead drug, but shares rise. Investors, take note. |
The Motley Fool
April 24, 2008
Brian Lawler |
FDA Stings Genzyme Earnings A nasty surprise hurts the drug developer's first quarter results. |
The Motley Fool
January 9, 2008
Brian Lawler |
Tracking Genzyme The biopharma updates investors on what to expect for 2008. |
The Motley Fool
July 12, 2006
Brian Lawler |
Genzyme Continues to Deliver The biopharmaceutical company releases their second quarter earnings announcement. The stock is up sharply today, almost 8%, after Genzyme reported earnings of $0.68 a share. |
The Motley Fool
September 23, 2010
Ryan McBride |
Genzyme Boss Not Ready to Sell to Sanofi The Dutch-born CEO is known for his tight control of decisions made at Genzyme, even to a fault. |
The Motley Fool
January 19, 2007
Karl Thiel |
The Best Drug Stock for 2007: Momenta Investors, swing for the fences with this drug company. |
The Motley Fool
January 5, 2010
Brian Orelli |
A Deal Manufactured by Necessity Genzyme gets some help from a new friend. |
